• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Wellcome Open Res . Estimating the duration of seropositivity of human seasonal coronaviruses using seroprevalence studies

tetano

Editor, Senior Moderator
Wellcome Open Res


. 2021 Jun 3;6:138.
doi: 10.12688/wellcomeopenres.16701.1. eCollection 2021.
Estimating the duration of seropositivity of human seasonal coronaviruses using seroprevalence studies


Eleanor M Rees[SUP] 1 2 [/SUP], Naomi R Waterlow[SUP] 1 [/SUP], Centre for the Mathematical Modelling of Infectious Diseases COVID-19 Working Group; Rachel Lowe[SUP] 1 2 [/SUP], Adam J Kucharski[SUP] 1 [/SUP]



Affiliations

Abstract

Background: The duration of immunity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is still uncertain, but it is of key clinical and epidemiological importance. Seasonal human coronaviruses (HCoV) have been circulating for longer and, therefore, may offer insights into the long-term dynamics of reinfection for such viruses. Methods: Combining historical seroprevalence data from five studies covering the four circulating HCoVs with an age-structured reverse catalytic model, we estimated the likely duration of seropositivity following seroconversion. Results: We estimated that antibody persistence lasted between 0.9 (95% Credible interval: 0.6 - 1.6) and 3.8 (95% CrI: 2.0 - 7.4) years. Furthermore, we found the force of infection in older children and adults (those over 8.5 [95% CrI: 7.5 - 9.9] years) to be higher compared with young children in the majority of studies. Conclusions: These estimates of endemic HCoV dynamics could provide an indication of the future long-term infection and reinfection patterns of SARS-CoV-2.

Keywords: Catalytic model; Seasonal coronavirus; Seroprevalence; waning immunity.
 
Back
Top